Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, Massachusetts, United States of America.
School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
PLoS Med. 2022 Jul 25;19(7):e1004055. doi: 10.1371/journal.pmed.1004055. eCollection 2022 Jul.
While the evidence for the clinical effectiveness of most noncommunicable disease (NCD) prevention and treatment interventions is well established, care delivery models and means of scaling these up in a variety of resource-constrained health systems are not. The objective of this review was to synthesize evidence on the current state of implementation research on priority NCD prevention and control interventions provided by health systems in low- and middle-income countries (LMICs).
On January 20, 2021, we searched MEDLINE and EMBASE databases from 1990 through 2020 to identify implementation research studies that focused on the World Health Organization (WHO) priority NCD prevention and control interventions targeting cardiovascular disease, cancer, diabetes, and chronic respiratory disease and provided within health systems in LMICs. Any empirical and peer-reviewed studies that focused on these interventions and reported implementation outcomes were eligible for inclusion. Given the focus on this review and the heterogeneity in aims and methodologies of included studies, risk of bias assessment to understand how effect size may have been compromised by bias is not applicable. We instead commented on the distribution of research designs and discussed about stronger/weaker designs. We synthesized extracted data using descriptive statistics and following the review protocol registered in PROSPERO (CRD42021252969). Of 9,683 potential studies and 7,419 unique records screened for inclusion, 222 eligible studies evaluated 265 priority NCD prevention and control interventions implemented in 62 countries (6% in low-income countries and 90% in middle-income countries). The number of studies published has been increasing over time. Nearly 40% of all the studies were on cervical cancer. With regards to intervention type, screening accounted for 49%, treatment for 39%, while prevention for 12% (with 80% of the latter focusing on prevention of the NCD behavior risk factors). Feasibility (38%) was the most studied implementation outcome followed by adoption (23%); few studies addressed sustainability. The implementation strategies were not specified well enough. Most studies used quantitative methods (86%). The weakest study design, preexperimental, and the strongest study design, experimental, were respectively employed in 25% and 24% of included studies. Approximately 72% of studies reported funding, with international funding being the predominant source. The majority of studies were proof of concept or pilot (88%) and targeted the micro level of health system (79%). Less than 5% of studies report using implementation research framework.
Despite growth in implementation research on NCDs in LMICs, we found major gaps in the science. Future studies should prioritize implementation at scale, target higher levels health systems (meso and macro levels), and test sustainability of NCD programs. They should employ designs with stronger internal validity, be more conceptually driven, and use mixed methods to understand mechanisms. To maximize impact of the research under limited resources, adding implementation science outcomes to effectiveness research and regional collaborations are promising.
虽然大多数非传染性疾病(NCD)预防和治疗干预措施的临床效果证据已经得到充分证实,但在各种资源有限的卫生系统中推广这些干预措施的护理提供模式和手段却没有得到证实。本研究的目的是综合评估在中低收入国家(LMICs)卫生系统中提供的优先 NCD 预防和控制干预措施的实施研究现状。
2021 年 1 月 20 日,我们检索了 1990 年至 2020 年期间的 MEDLINE 和 EMBASE 数据库,以确定重点关注世界卫生组织(WHO)优先 NCD 预防和控制干预措施的实施研究,这些干预措施针对心血管疾病、癌症、糖尿病和慢性呼吸道疾病,并在 LMICs 中的卫生系统内提供。任何关注这些干预措施并报告实施结果的经验性和同行评议研究都符合纳入标准。鉴于本研究的重点以及纳入研究的目标和方法的异质性,评估偏倚风险以了解效果大小如何因偏倚而受到影响并不适用。相反,我们对研究设计的分布进行了评论,并讨论了更有力/较弱的设计。我们使用描述性统计数据和按照在 PROSPERO(CRD42021252969)中注册的审查方案综合了提取的数据。在纳入的 9683 项潜在研究和 7419 项独特记录中,有 222 项符合条件的研究评估了在 62 个国家实施的 265 项优先 NCD 预防和控制干预措施(低收入国家占 6%,中等收入国家占 90%)。发表的研究数量一直在增加。所有研究中近 40%的研究是关于宫颈癌的。关于干预类型,筛查占 49%,治疗占 39%,而预防占 12%(其中 80%的预防重点是预防 NCD 行为危险因素)。可行性(38%)是研究最多的实施结果,其次是采用(23%);很少有研究关注可持续性。实施策略没有得到很好的说明。大多数研究都使用了定量方法(86%)。最弱的研究设计,前实验性设计,以及最强的研究设计,实验性设计,分别在纳入研究的 25%和 24%中使用。大约 72%的研究报告了资金情况,国际资金是主要来源。大多数研究是概念验证或试点研究(88%),针对卫生系统的微观层面(79%)。不到 5%的研究报告使用实施研究框架。
尽管在 LMICs 中开展了 NCD 实施研究,但我们发现该领域仍存在重大空白。未来的研究应优先考虑大规模实施,针对更高层次的卫生系统(中观和宏观层次),并测试 NCD 项目的可持续性。它们应该采用具有更强内部有效性的设计,更具概念驱动性,并使用混合方法来了解机制。为了在有限的资源下最大限度地发挥研究的影响,将实施科学结果添加到有效性研究中,并进行区域合作是很有前景的。